California: FDA Asked to Lift Mifepristone Restrictions
California and three other states are demanding the FDA ease restrictions on mifepristone, a critical drug used for medication abortions. This legal push highlights the medication’s strong safety record and the unnecessary hurdles current limitations create for access, notably for low-income and rural women. The states’ attorneys general argue that these restrictions unduly burden the healthcare system, emphasizing the urgency of timely access to this essential medication. This move follows Senate testimony referencing the FDA’s review. News Directory 3 is following this developing story closely. What further developments await regarding mifepristone access?
States Push FDA on Mifepristone Access, Citing Safety record
Updated June 6, 2025
California, along with Massachusetts, New York, and New Jersey, are pressuring the Food and Drug Administration to loosen restrictions on mifepristone, a medication used in abortions.The states filed a petition Thursday, emphasizing the drug’s established safety and arguing current limitations create needless barriers to access.
CA Attorney General Rob Bonta stated the medication is crucial for women, especially those with low incomes or in underserved areas, who require timely healthcare. The attorneys general argue the restrictions place an undue burden on the healthcare system.
The petition references recent Senate testimony where Health and Human Services Secretary Robert F. Kennedy Jr. said he instructed FDA administrator Martin Makary to conduct a thorough review of mifepristone and its labeling.